172 related articles for article (PubMed ID: 33194157)
1. NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature.
Catalano G; Niscola P; Banella C; Diverio D; Trawinska MM; Fratoni S; Iazzoni R; De Fabritiis P; Abruzzese E; Noguera NI
Mediterr J Hematol Infect Dis; 2020; 12(1):e2020083. PubMed ID: 33194157
[TBL] [Abstract][Full Text] [Related]
2. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.
Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Höglund M; Lehmann S; Derolf Å; Deneberg S; Antunovic P; Cammenga J; Möllgård L; Wennström L; Lilljebjörn H; Rissler M; Fioretos T; Lazarevic VL
Genes Chromosomes Cancer; 2021 Jun; 60(6):426-433. PubMed ID: 33433047
[TBL] [Abstract][Full Text] [Related]
3. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
4. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
Salem A; Loghavi S; Tang G; Huh YO; Jabbour EJ; Kantarjian H; Wang W; Hu S; Luthra R; Medeiros LJ; Khoury JD
Am J Hematol; 2017 Jun; 92(6):520-528. PubMed ID: 28253536
[TBL] [Abstract][Full Text] [Related]
5. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.
Alikian M; Gale RP; Apperley JF; Foroni L
Biomol Detect Quantif; 2017 Mar; 11():4-20. PubMed ID: 28331814
[TBL] [Abstract][Full Text] [Related]
6. A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.
Piedimonte M; Ottone T; Alfonso V; Ferrari A; Conte E; Divona M; Bianchi MP; Ricciardi MR; Mirabilii S; Licchetta R; Campagna A; Cicconi L; Galassi G; Pelliccia S; Leporace A; Lo Coco F; Tafuri A
BMC Cancer; 2019 Jan; 19(1):50. PubMed ID: 30630459
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions.
Shao L; Miller S; Keller-Ramey J; Zhang Y; Roulston D
Cancer Genet; 2015; 208(7-8):396-403. PubMed ID: 26186983
[TBL] [Abstract][Full Text] [Related]
8. Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion.
Blackburn PR; Huang L; Dalovisio A; Pitel BA; Chen D; Oliveira JL; Wood AJ; Smadbeck JB; Johnson SH; Vasmatzis G; Haferlach C; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Peterson JF
Cancer Genet; 2020 Feb; 241():67-71. PubMed ID: 31902694
[TBL] [Abstract][Full Text] [Related]
9. Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations.
Bacher U; Haferlach T; Alpermann T; Zenger M; Hochhaus A; Beelen DW; Uppenkamp M; Rummel M; Kern W; Schnittger S; Haferlach C
Br J Haematol; 2011 Mar; 152(6):713-20. PubMed ID: 21275954
[TBL] [Abstract][Full Text] [Related]
10. Comparative Expression Analysis of Breakpoint Cluster Region-Abelson Oncogene in Leukemia Patients.
Arshad F; Ali A; Rehman G; Halim SA; Waqas M; Khalid A; Abdalla AN; Khan A; Al-Harrasi A
ACS Omega; 2023 Feb; 8(6):5975-5982. PubMed ID: 36816652
[TBL] [Abstract][Full Text] [Related]
11. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
Tabarestani S; Movafagh A
Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
[TBL] [Abstract][Full Text] [Related]
12. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia.
Antoszewska-Smith J; Pawlowska E; Blasiak J
Acta Biochim Pol; 2017; 64(1):1-10. PubMed ID: 27904889
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
McCarron SL; O'Connor LM; Langabeer SE; Conneally E
Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.
Neuendorff NR; Burmeister T; Dörken B; Westermann J
Ann Hematol; 2016 Aug; 95(8):1211-21. PubMed ID: 27297971
[TBL] [Abstract][Full Text] [Related]
15. Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.
Tsubaki M; Takeda T; Kino T; Sakai K; Itoh T; Imano M; Nakayama T; Nishio K; Satou T; Nishida S
Oncotarget; 2017 Jun; 8(24):38717-38730. PubMed ID: 28418880
[TBL] [Abstract][Full Text] [Related]
16. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
17. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
18. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
19. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
20. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
